F.D.A. Advisers Meets on Merck’s Covid Pill
Representatives from Merck and from the F.D.A. reviewed the results of safety studies in cells, animals, and clinical trials. “The overall risk of mutagenicity in humans is considered low,” Dr. Aimee Hodowanec, a senior medical officer at the F.D.A., said at the meeting, referring to the potential for the drug to induce mutations in the…